INTRAHEPATIC CHOLANGIOCARCINOMA

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This global Phase 3 trial is testing whether adding the experimental immunotherapy rilvegostomig to standard chemotherapy helps people with advanced biliary tract cancer live longer, compared to adding the approved drug durvalumab. About 1,100 participants with inoperable or meta…

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…

This study tests two surgical techniques for bile duct cancer that has spread to nearby lymph nodes. One method removes the bile duct completely to take out all affected lymph nodes, while the other leaves the bile duct in place but may leave some lymph tissue behind. The goal is…

This phase 3 trial is testing whether giving a targeted therapy after initial standard chemotherapy can help people with advanced biliary cancer live longer without their disease getting worse. Participants must have a tumor with a specific genetic change and stable disease after…

This study tests a new drug called ivonescimab against standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were in the SAFIR-ABC10 trial will be randomly assigned to receive either ivonescim…

This study is testing a treatment strategy for biliary tract cancer, a group of aggressive cancers with poor survival. The approach combines hepatic arterial infusion chemotherapy (HAIC) with systemic drugs like bevacizumab and an immunotherapy. The goal is to shrink tumors and i…

This study tests whether combining two drugs (pemigatinib and durvalumab) can shrink or control advanced bile duct cancer that has a specific FGFR2 gene change. About 38 adults whose cancer has not responded to prior treatment will receive daily pills and an IV infusion every 3 w…

This study tests a new combination of drugs for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. About 35 participants will receive an oral drug called chidamide along with standard chemotherapy and immunotherapy. The…

This study compares standard chemotherapy (gemcitabine and oxaliplatin) alone versus the same drugs plus a liver-directed chemotherapy (HAI FUDR/dexamethasone) in people with bile duct cancer that has spread within the liver but cannot be removed surgically. About 164 adults with…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) before and after surgery can improve outcomes for people with a type of bile duct cancer called intrahepatic cholangiocarcinoma. The trial will enroll 24 adul…

This study tests whether a liver transplant after a combination of targeted internal radiation (SIRT with Yttrium-90) and chemotherapy can improve 3-year survival in people with locally advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be surgicall…

This study tests a new combination of four drugs—two standard chemotherapies plus an immunotherapy and a cholesterol drug—in people with advanced bile duct cancer. All 29 participants will receive the same treatment. Researchers will check how many patients see their tumors shrin…

This study looks at whether a liver transplant can help people with a certain type of advanced bile duct cancer that hasn't spread. Participants will first receive chemotherapy to control the cancer, then undergo a liver transplant. The goal is to see if this approach helps them …

This study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …

This study is testing a new way to deliver radiation therapy for liver cancer. Instead of multiple sessions over weeks, patients receive a single, high-dose treatment guided by real-time MRI scans. The approach aims to be more precise and convenient. The trial will enroll 62 adul…

This study tests two treatments for a type of bile duct cancer that cannot be surgically removed. One delivers chemotherapy directly to the liver through a pump, and the other uses tiny radioactive beads injected into the tumor's blood supply. Both are given alongside standard ch…

This study tests a pump that delivers chemotherapy directly to the liver for people with colorectal cancer or bile duct cancer that has spread to the liver. The goal is to see if the pump is safe and if patients can get their pump refilled at a local clinic instead of always trav…

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy or the targeted drug lenvatinib can help people with advanced biliary tract cancer live longer and control their tumors better. The study will enroll 60 adults whose cancer …

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the combination treatment. …

This phase 2 trial is testing whether adding two immunotherapy drugs (tuvonralimab and iparomlimab) to standard chemotherapy before surgery can improve outcomes for people with bile duct or gallbladder cancer. About 45 adults with resectable or borderline-resectable cancer will r…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This study tests a combination of four drugs—gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab—in people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not been treated before. The goal is to see if this mix can shrink tumors and improve surv…

This study aims to develop a simple blood test that can tell the difference between two common types of liver cancer: hepatocellular carcinoma and cholangiocarcinoma. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal is to help …

This study tests whether people with liver cancer can be safely treated as outpatients instead of staying in the hospital after a procedure that delivers treatment directly to the liver's blood supply. About 206 patients will be randomly assigned to either outpatient or standard …

This study looks at whether the amount of healthy liver removed during surgery can predict liver failure afterward. Researchers will create a risk model based on 1,600 patients who had liver surgery for cancer. The goal is to help doctors identify high-risk patients before surger…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a traditional tissue biopsy. The goal is to make it easier and less invasive to identify which patients might benefit from targeted therapi…

This study looks at whether CT scans can help doctors predict how well chemotherapy will work for people with pancreatic or liver cancer. About 259 adults with these cancers will get CT scans before and during treatment. The goal is to see if changes in the scan can tell if the t…

This study looks at whether emotional disorders like depression and anxiety affect how well immunotherapy works in people with liver cancer. Researchers will follow 651 patients and compare treatment outcomes between those with and without emotional distress. The goal is to under…